SMARCA4 Regulates Spatially Restricted Metabolic Plasticity in 3D Multicellular Tissue
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Genome-Wide CRISPR Screening Identifies BRD9 As a Druggable Component Of
bioRxiv preprint doi: https://doi.org/10.1101/2021.02.04.429732; this version posted February 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Genome-Wide CRISPR Screening Identifies BRD9 as a Druggable Component of 2 Interferon-Stimulated Gene Expression and Antiviral Activity 3 Jacob Börolda,b,†, Davide Elettoa,†,#, Idoia Busnadiegoa, Nina K. Maira,b, Eva Moritza, 4 Samira Schiefera,b, Nora Schmidta,$, Philipp P. Petricc,d, W. Wei-Lynn Wonge, Martin 5 Schwemmlec & Benjamin G. Halea,* 6 7 aInstitute of Medical Virology, University of Zurich, Zurich, Switzerland. 8 bLife Science Zurich Graduate School, ETH and University of Zurich, Zurich, 9 Switzerland. 10 cInstitute of Virology, Freiburg University Medical Center, Faculty of Medicine, University 11 of Freiburg, Freiburg, Germany. 12 dSpemann Graduate School of Biology and Medicine, University of Freiburg, Freiburg, 13 Germany. 14 eInstitute of Experimental Immunology, University of Zurich, Zurich, Switzerland. 15 *Correspondence: Benjamin G. Hale, [email protected] 16 †Equal first authors listed in alphabetical order. 17 #Present address: Department of Biosystems Science and Engineering, ETH Zurich, 18 Basel, Switzerland. 19 $Present address: Helmholtz Institute for RNA-based Infection Research, Helmholtz- 20 Center for Infection Research, Wurzburg, Germany. 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.02.04.429732; this version posted February 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. -
Genomic and Expression Profiling of Chromosome 17 in Breast Cancer Reveals Complex Patterns of Alterations and Novel Candidate Genes
[CANCER RESEARCH 64, 6453–6460, September 15, 2004] Genomic and Expression Profiling of Chromosome 17 in Breast Cancer Reveals Complex Patterns of Alterations and Novel Candidate Genes Be´atrice Orsetti,1 Me´lanie Nugoli,1 Nathalie Cervera,1 Laurence Lasorsa,1 Paul Chuchana,1 Lisa Ursule,1 Catherine Nguyen,2 Richard Redon,3 Stanislas du Manoir,3 Carmen Rodriguez,1 and Charles Theillet1 1Ge´notypes et Phe´notypes Tumoraux, EMI229 INSERM/Universite´ Montpellier I, Montpellier, France; 2ERM 206 INSERM/Universite´ Aix-Marseille 2, Parc Scientifique de Luminy, Marseille cedex, France; and 3IGBMC, U596 INSERM/Universite´Louis Pasteur, Parc d’Innovation, Illkirch cedex, France ABSTRACT 17q12-q21 corresponding to the amplification of ERBB2 and collinear genes, and a large region at 17q23 (5, 6). A number of new candidate Chromosome 17 is severely rearranged in breast cancer. Whereas the oncogenes have been identified, among which GRB7 and TOP2A at short arm undergoes frequent losses, the long arm harbors complex 17q21 or RP6SKB1, TBX2, PPM1D, and MUL at 17q23 have drawn combinations of gains and losses. In this work we present a comprehensive study of quantitative anomalies at chromosome 17 by genomic array- most attention (6–10). Furthermore, DNA microarray studies have comparative genomic hybridization and of associated RNA expression revealed additional candidates, with some located outside current changes by cDNA arrays. We built a genomic array covering the entire regions of gains, thus suggesting the existence of additional amplicons chromosome at an average density of 1 clone per 0.5 Mb, and patterns of on 17q (8, 9). gains and losses were characterized in 30 breast cancer cell lines and 22 Our previous loss of heterozygosity mapping data pointed to the primary tumors. -
Increased ACTL6A Occupancy Within Mswi/SNF Chromatin Remodelers
bioRxiv preprint doi: https://doi.org/10.1101/2021.03.22.435873; this version posted March 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Increased ACTL6A Occupancy Within mSWI/SNF Chromatin Remodelers Drives Human Squamous Cell Carcinoma Chiung-Ying Chang1,2,7, Zohar Shipony3,7, Ann Kuo1,2, Kyle M. Loh4,5, William J. Greenleaf3,6, Gerald R. Crabtree1,2,5* 1Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, California 94305, USA. 2Department of Pathology, Stanford University School of Medicine, Stanford, California 94305, USA. 3Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA. 4Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California 94305, USA. 5Department of Developmental Biology, Stanford University School of Medicine, Stanford, California 94305, USA. 6Department of Applied Physics, Stanford University, Stanford, California 94305, USA. 7These authors contributed equally. *Corresponding author: Gerald R. Crabtree, [email protected] Summary Mammalian SWI/SNF (BAF) chromatin remodelers play dosage-sensitive roles in many human malignancies and neurologic disorders. The gene encoding the BAF subunit, ACTL6A, is amplified at an early stage in the development of squamous cell carcinomas (SCCs), but its oncogenic role remains unclear. Here we demonstrate that ACTL6A overexpression leads to its stoichiometric assembly into BAF complexes and drives its interaction and engagement with specific regulatory regions in the genome. In normal epithelial cells, ACTL6A was sub-stoichiometric to other BAF subunits. However, increased ACTL6A levels by ectopic expression or in SCC cells led to near-saturation of ACTL6A within BAF complexes. -
Transcriptional Modulator ZBED6 Affects Cell Cycle and Growth of Human Colorectal Cancer Cells
Transcriptional modulator ZBED6 affects cell cycle and growth of human colorectal cancer cells Muhammad Akhtar Alia,1, Shady Younisb,c,1, Ola Wallermand, Rajesh Guptab, Leif Anderssonb,d,e,1,2, and Tobias Sjöbloma,1 aScience For Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, SE-751 85 Uppsala, Sweden; bScience for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, SE-751 85 Uppsala, Sweden; cDepartment of Animal Production, Ain Shams University, Shoubra El-Kheima, 11241 Cairo, Egypt; dDepartment of Animal Breeding and Genetics, Swedish University of Agricultural Sciences, SE-75007 Uppsala, Sweden; and eDepartment of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX 77843 Contributed by Leif Andersson, May 15, 2015 (sent for review December 10, 2014; reviewed by Jan-Ake Gustafsson) The transcription factor ZBED6 (zinc finger, BED-type containing 6) (QTN) with a large impact on body composition (muscle growth is a repressor of IGF2 whose action impacts development, cell pro- and fat deposition); mutant animals showed threefold higher IGF2 liferation, and growth in placental mammals. In human colorectal expression in postnatal muscle (11). ZBED6 was identified as the cancers, IGF2 overexpression is mutually exclusive with somatic nuclear factor specifically binding the wild-type IGF2 sequence but mutations in PI3K signaling components, providing genetic evi- not the mutated site. ChIP sequencing (ChIP-seq) in mouse C2C12 dence for a role in the PI3K pathway. To understand the role of cells identified more than 1,200 putative ZBED6 target genes, in- ZBED6 in tumorigenesis, we engineered and validated somatic cell cluding 262 genes encoding transcription factors (6). -
Cellular and Molecular Signatures in the Disease Tissue of Early
Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of -
Ten Commandments for a Good Scientist
Unravelling the mechanism of differential biological responses induced by food-borne xeno- and phyto-estrogenic compounds Ana María Sotoca Covaleda Wageningen 2010 Thesis committee Thesis supervisors Prof. dr. ir. Ivonne M.C.M. Rietjens Professor of Toxicology Wageningen University Prof. dr. Albertinka J. Murk Personal chair at the sub-department of Toxicology Wageningen University Thesis co-supervisor Dr. ir. Jacques J.M. Vervoort Associate professor at the Laboratory of Biochemistry Wageningen University Other members Prof. dr. Michael R. Muller, Wageningen University Prof. dr. ir. Huub F.J. Savelkoul, Wageningen University Prof. dr. Everardus J. van Zoelen, Radboud University Nijmegen Dr. ir. Toine F.H. Bovee, RIKILT, Wageningen This research was conducted under the auspices of the Graduate School VLAG Unravelling the mechanism of differential biological responses induced by food-borne xeno- and phyto-estrogenic compounds Ana María Sotoca Covaleda Thesis submitted in fulfillment of the requirements for the degree of doctor at Wageningen University by the authority of the Rector Magnificus Prof. dr. M.J. Kropff, in the presence of the Thesis Committee appointed by the Academic Board to be defended in public on Tuesday 14 September 2010 at 4 p.m. in the Aula Unravelling the mechanism of differential biological responses induced by food-borne xeno- and phyto-estrogenic compounds. Ana María Sotoca Covaleda Thesis Wageningen University, Wageningen, The Netherlands, 2010, With references, and with summary in Dutch. ISBN: 978-90-8585-707-5 “Caminante no hay camino, se hace camino al andar. Al andar se hace camino, y al volver la vista atrás se ve la senda que nunca se ha de volver a pisar” - Antonio Machado – A mi madre. -
Genetic Variants on Chromosome 1Q41 Influence Ocular Axial Length and High Myopia
Genetic Variants on Chromosome 1q41 Influence Ocular Axial Length and High Myopia Qiao Fan1, Veluchamy A. Barathi2,3, Ching-Yu Cheng1,2,3, Xin Zhou1, Akira Meguro4, Isao Nakata5,6, Chiea-Chuen Khor2,7,8,9, Liang-Kee Goh1,10,11, Yi-Ju Li12,13, Wan’e Lim2, Candice E. H. Ho2, Felicia Hawthorne13, Yingfeng Zheng2, Daniel Chua2, Hidetoshi Inoko14, Kenji Yamashiro5, Kyoko Ohno- Matsui15, Keitaro Matsuo16, Fumihiko Matsuda6, Eranga Vithana2,3, Mark Seielstad17, Nobuhisa Mizuki4, Roger W. Beuerman2,3,10, E.-Shyong Tai1,18, Nagahisa Yoshimura5, Tin Aung2,3, Terri L. Young10,13, Tien-Yin Wong1,2,3,19, Yik-Ying Teo1,7,20,21.*, Seang-Mei Saw1,2,3,10,20.* 1 Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, 2 Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore, 3 Department of Ophthalmology, National University of Singapore, Singapore, Singapore, 4 Department of Ophthalmology, Yokohama City University School of Medicine, Yokohama, Japan, 5 Department of Ophthalmology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 6 Center for Genomic Medicine and Inserm U.852, Kyoto University Graduate School of Medicine, Kyoto, Japan, 7 Genome Institute of Singapore, Agency for Science, Technology, and Research, Singapore, Singapore, 8 Centre for Molecular Epidemiology, National University of Singapore, Singapore, Singapore, 9 Department of Pediatrics, National University of Singapore, Singapore, Singapore, 10 Duke–National University of Singapore Graduate Medical School, Singapore, -
DNA Sequences of Ca2+-Atpase Gene in Rice KDML 105
Kasetsart J. (Nat. Sci.) 40 : 472 - 485 (2006) DNA Sequences of Ca2+-ATPase Gene in Rice KDML 105 Sakonwan Prasitwilai1, Sripan Pradermwong2, Amara Thongpan3 and Mingkwan Mingmuang1* ABSTRACT Total RNA isolated from the leaves of KDML 105 rice was used as template to make complementary DNA (cDNA). Primer combinations of CA1-CA10 which were designed from Lycopersicon esculentum and Arabidopsis thaliana Ca2+-ATPase gene sequence were used. The nucleotide sequences amplified from 7 primer combinations gave 2,480 bp (fragment A). This fragment was found to be 99% homology to that of the putative calcium ATPase of Oryza sativa (Japonica cultivar-group) as shown in the GenBank. Amplification of 3v end fragment done by Rapid Amplification of cDNA Ends (3vRACE) technique using 3vGSP1, 3vGSP2, and 3vUAP as primers gave a DNA fragment of 933 bp having an overlapping region with DNA fragment A, which resulted in the combined length of 2,944 bp (fragment B). To find the sequence of 5v end, 5vRACE technique was used having 5vGSP1, 5vGSP2, 5v AP and 5vUAP as primers. It gave a DNA fragment of 473 bp showing an overlapping region with DNA fragment B, which ultimately resulted in the combined length of 3,331 bp (total CA). The deduced 1,008 amino acid sequence of total CA showed 99% homology to putative calcium ATPase of O. sativa (Japonica cultivar-group) cv. Nipponbare. The higher percent homology of this Ca2+-ATPase gene in KDML105 to that of O. sativa cv. Nipponbare (99%) than to O. sativa cv. IR36 (89%) was not as anticipated since both KDML105 and O. -
Dissection of the Cellular Function of the ZBED6 Transcription Factor in Mouse
bioRxiv preprint doi: https://doi.org/10.1101/540914; this version posted February 5, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Dissection of the cellular function of the ZBED6 transcription factor in mouse 2 myoblast cells using gene editing, RNAseq and proteomics 3 4 Shady Younis1, Rakan Naboulsi1, Xuan Wang2, Xiaofang Cao1, Mårten Larsson1, Ernest 5 Sargsyan2, Peter Bergsten2, Nils Welsh2, Leif Andersson1,3,4 6 7 1Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala 8 University, SE-751 23 Uppsala, Sweden. 2Science for Life Laboratory, Department of Medical 9 Cell Biology, Uppsala University, SE-751 23 Uppsala, Sweden. 3Department of Animal 10 Breeding and Genetics, Swedish University of Agricultural Sciences, SE-75007 Uppsala, 11 Sweden. 4Department of Veterinary Integrative Biosciences, Texas A&M University, College 12 Station, TX 77843, USA. 13 14 15 1 bioRxiv preprint doi: https://doi.org/10.1101/540914; this version posted February 5, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 16 SUMMARY 17 The transcription factor ZBED6 acts as a repressor of Igf2 and affects directly or indirectly the 18 transcriptional regulation of thousands of genes. Here, we use gene editing in mouse C2C12 19 myoblasts and show that ZBED6 regulates Igf2 exclusively through its binding site 5′-GGCTCG- Δ 20 3′ in intron 1 of Igf2. Deletion of this motif (Igf2 GGCT) or complete ablation of Zbed6 leads to 21 ~20-fold up-regulation of IGF2 protein. -
Transcriptional Modulator ZBED6 Affects Cell Cycle and Growth of Human Colorectal Cancer Cells
Transcriptional modulator ZBED6 affects cell cycle and growth of human colorectal cancer cells Muhammad Akhtar Alia,1, Shady Younisb,c,1, Ola Wallermand, Rajesh Guptab, Leif Anderssonb,d,e,1,2, and Tobias Sjöbloma,1 aScience For Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, SE-751 85 Uppsala, Sweden; bScience for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, SE-751 85 Uppsala, Sweden; cDepartment of Animal Production, Ain Shams University, Shoubra El-Kheima, 11241 Cairo, Egypt; dDepartment of Animal Breeding and Genetics, Swedish University of Agricultural Sciences, SE-75007 Uppsala, Sweden; and eDepartment of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX 77843 Contributed by Leif Andersson, May 15, 2015 (sent for review December 10, 2014; reviewed by Jan-Ake Gustafsson) The transcription factor ZBED6 (zinc finger, BED-type containing 6) (QTN) with a large impact on body composition (muscle growth is a repressor of IGF2 whose action impacts development, cell pro- and fat deposition); mutant animals showed threefold higher IGF2 liferation, and growth in placental mammals. In human colorectal expression in postnatal muscle (11). ZBED6 was identified as the cancers, IGF2 overexpression is mutually exclusive with somatic nuclear factor specifically binding the wild-type IGF2 sequence but mutations in PI3K signaling components, providing genetic evi- not the mutated site. ChIP sequencing (ChIP-seq) in mouse C2C12 dence for a role in the PI3K pathway. To understand the role of cells identified more than 1,200 putative ZBED6 target genes, in- ZBED6 in tumorigenesis, we engineered and validated somatic cell cluding 262 genes encoding transcription factors (6). -
Datasheet A07237-1 Anti-Carbonic Anhydrase 10/CA10 Antibody
Product datasheet Anti-Carbonic anhydrase 10/CA10 Antibody Catalog Number: A07237-1 BOSTER BIOLOGICAL TECHNOLOGY Special NO.1, International Enterprise Center, 2nd Guanshan Road, Wuhan, China Web: www.boster.com.cn Phone: +86 27 67845390 Fax: +86 27 67845390 Email: [email protected] Basic Information Product Name Anti-Carbonic anhydrase 10/CA10 Antibody Gene Name CA10 Source Rabbit IgG Species Reactivity human Tested Application WB,Direct ELISA Contents 500ug/ml antibody with PBS ,0.02% NaN3 , 1mg BSA and 50% glycerol. Immunogen E.coli-derived human Carbonic anhydrase 10/CA10 recombinant protein (Position: M1-K328). Purification Immunogen affinity purified. Observed MW Dilution Ratios Western blot: 1:500-2000 Direct ELISA: 1:100-1000 Storage 12 months from date of receipt,-20℃ as supplied.6 months 2 to 8℃ after reconstitution. Avoid repeated freezing and thawing Background Information Carbonic anhydrase-related protein 10 is an enzyme that in humans is encoded by the CA10 gene. This gene encodes a protein that belongs to the carbonic anhydrase family of zinc metalloenzymes, which catalyze the reversible hydration of carbon dioxide in various biological processes. The protein encoded by this gene is an acatalytic member of the alpha-carbonic anhydrase subgroup, and it is thought to play a role in the central nervous system, especially in brain development. Multiple transcript variants encoding the same protein have been found for this gene. Reference Anti-Carbonic anhydrase 10/CA10 Antibody被引用在0文献中。 暂无引用 FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC AND CLINICAL USE. 1 Product datasheet Anti-Carbonic anhydrase 10/CA10 Antibody Catalog Number: A07237-1 BOSTER BIOLOGICAL TECHNOLOGY Special NO.1, International Enterprise Center, 2nd Guanshan Road, Wuhan, China Web: www.boster.com.cn Phone: +86 27 67845390 Fax: +86 27 67845390 Email: [email protected] Selected Validation Data FOR RESEARCH USE ONLY. -
TP53 Mutations As a Driver of Metastasis Signaling in Advanced Cancer Patients
cancers Article TP53 Mutations as a Driver of Metastasis Signaling in Advanced Cancer Patients Ritu Pandey 1,2,*, Nathan Johnson 3, Laurence Cooke 1, Benny Johnson 4, Yuliang Chen 1, Manjari Pandey 5, Jason Chandler 5 and Daruka Mahadevan 6,* 1 Cancer Center, University of Arizona, Tucson, AZ 85724, USA; [email protected] (L.C.); [email protected] (Y.C.) 2 Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ 85724, USA 3 School of Medicine, Vanderbilt University, Nashville, TN 37325, USA; [email protected] 4 MD Anderson Cancer Center, Houston, TX 77030, USA; [email protected] 5 West Cancer Center, 7945 Wolf River Blvd, Germantown, TN 38138, USA; [email protected] (M.P.); [email protected] (J.C.) 6 Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX 78229, USA * Correspondence: [email protected] (R.P.); [email protected] (D.M.) Simple Summary: The DNA sequencing of cancer provides information about specific genetic changes that could help with treatment decisions. Tumors from different tissues change over time and acquire new genetic changes particularly with treatment. Our study analyzed the gene changes of 171 advanced cancer patients. We predicted that tumors gain new mutations but that TP53 mutations (guardian of the human genome) are conserved as the tumor progresses from primary to metastatic sites and across tissue types. We analyzed the primary and metastatic site gene changes in 25 tissue types and conducted in-depth analysis of colon and lung cancer sites for substantial changes. TP53 site specific mutations were different across tissue types and suggest different molecular changes.